Aiosyn, a company that develops AI-powered pathology algorithms for clinical diagnostics and life sciences, was awarded early-phase funding of Eur 250.000 by NWO (Dutch Research Council). This additional funding allows Aiosyn to accelerate its mission: increasing the adoption of artificial intelligence in pathology diagnostics and improving the chances of cancer patients worldwide.
Related news items
Boosting the startup ecosystem in Nijmegen!22 June 2023
TechleapNL, Radboud university, Radboudumc and the municipality of Nijmegen hosted a successful event where innovative health and hightech startups shared their view on the challenges and opportunities for the local startup ecosystem.read more
Aiosyn selected as finalist for OostNL's Startversneller vote now!18 October 2022
The 6 finalists of the election “Starter with impact Eastern Netherlands 2022” have been announced and Radboudumc’s Aiosyn is one of them.read more